KENILWORTH, N.J., Dec. 14 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Feb. 26, 2008, to shareholders of record at the close of business on Feb. 1, 2008. As of Sept. 30, 2007, there were 1,619,721,867 common shares outstanding.
The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferred Stock. Payment will be made on Feb. 15, 2008, to holders of record at the close of business on Feb. 1, 2008. As of Sept. 30, 2007, there were 10,000,000 shares of 2007 Mandatory Convertible Preferred Stock outstanding.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
CONTACT: Media: Fred Malley, +1-908-298-7428, or Investors: Alex Kelly or
Robyn Brown, +1-908-298-7436, all of Schering-Plough Corporation
Web site: http://www.schering-plough.com/
Company News On-Call: http://www.prnewswire.com/comp/777050.html/
